The purpose of the study is to evaluate whether evolocumab, when added to ongoing lipid-lowering therapy (LLT), is more effective than LLT alone in stabilizing and reducing carotid plaque. The study will observe participants over a period of 12 months. At the 6-month mark, researchers will assess whether the plaque has become more stable, meaning it has fewer ulcerations and a more regular shape. By the end of 12 months, the study will check if there is a reduction in the narrowing of the arteries.

Participants in the study will receive either evolocumab or a placebo in addition to their current LLT. The treatment is given through an injection, which can be administered either intravenously (IV) or under the skin (subcutaneously). The study aims to provide insights into the potential benefits of evolocumab for individuals with carotid stenosis, potentially leading to improved treatment options in the future.

The purpose of the study is to determine if a short course of omalizumab can reduce the activation of mast cells within atherosclerotic plaques, which are fatty deposits that can build up in the arteries. Participants in the study will receive either omalizumab or a placebo, which is a substance with no active medication. The study will involve regular monitoring and assessments to observe the effects of the treatment on the participants’ condition.

Throughout the study, various health parameters will be measured to evaluate the impact of omalizumab on inflammation and other related factors. These include the levels of certain immune cells and proteins in the blood and within the plaques themselves. The study aims to provide insights into whether omalizumab can help manage atherosclerosis by targeting mast cell activity, potentially leading to new treatment options for patients with carotid artery stenosis.